The other retrospective cohort study [65] involved 77 moderate patients with COVID-19, 7 were treated with nebulized IFN-α2b, 24 with umifenovir, 46 with combined treatment of IFN-α2b plus umifenovir. Here, IFNA2 is linked to COVID-19.